Latest Insider Transactions at Dyne Therapeutics, Inc. (DYN)
This section provides a real-time view of insider transactions for Dyne Therapeutics, Inc. (DYN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Dyne Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Dyne Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
802
-1.1%
|
$3,208
$4.95 P/Share
|
|
Jun 14
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
504
-0.83%
|
$2,016
$4.95 P/Share
|
|
Jun 14
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
333
-1.23%
|
$1,332
$4.95 P/Share
|
|
Mar 11
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
693
-1.27%
|
$5,544
$8.73 P/Share
|
|
Mar 11
2022
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
3,384
-1.58%
|
$27,072
$8.73 P/Share
|
|
Mar 11
2022
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
640
-0.96%
|
$5,120
$8.73 P/Share
|
|
Mar 11
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
765
-1.04%
|
$6,120
$8.73 P/Share
|
|
Mar 11
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
481
-0.79%
|
$3,848
$8.73 P/Share
|
|
Mar 11
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
308
-1.13%
|
$2,464
$8.73 P/Share
|
|
Mar 02
2022
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,617
-7.77%
|
$44,936
$8.56 P/Share
|
|
Dec 10
2021
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,524
+40.18%
|
-
|
|
Dec 10
2021
|
Joshua T Brumm CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
118,190
+35.61%
|
-
|
|
Dec 10
2021
|
Wildon Farwell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,307
+23.58%
|
-
|
|
Dec 10
2021
|
Susanna Gatti High Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,315
+35.34%
|
-
|
|
Dec 10
2021
|
Jonathan Mc Neill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,311
+29.34%
|
-
|
|
Dec 10
2021
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
16,696
+37.95%
|
-
|
|
Oct 01
2021
|
Joshua T Brumm CEO & President |
SELL
Bona fide gift
|
Direct |
3,500
-3.53%
|
-
|
|
Sep 23
2021
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,451
-6.83%
|
$41,667
$17.22 P/Share
|
|
Sep 21
2021
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
827
-4.43%
|
$13,232
$16.11 P/Share
|
|
Sep 21
2021
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
4,584
-4.42%
|
$73,344
$16.11 P/Share
|
|
Sep 21
2021
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
729
-2.0%
|
$11,664
$16.11 P/Share
|
|
Sep 21
2021
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
492
-4.43%
|
$7,872
$16.11 P/Share
|
|
Sep 20
2021
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
617
-3.2%
|
$9,255
$15.61 P/Share
|
|
Sep 20
2021
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
3,425
-3.2%
|
$51,375
$15.61 P/Share
|
|
Sep 20
2021
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
545
-1.48%
|
$8,175
$15.61 P/Share
|
|
Sep 20
2021
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
367
-3.2%
|
$5,505
$15.61 P/Share
|
|
Jul 13
2021
|
Atlas Venture Fund Xi, L.P. |
SELL
Other acquisition or disposition
|
Direct |
814,013
-10.0%
|
-
|
|
Mar 02
2021
|
Wildon Farwell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Sep 21
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
660,000
+19.05%
|
$12,540,000
$19.0 P/Share
|
|
Sep 21
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,145,045
+50.0%
|
-
|
|
Sep 21
2020
|
Logos Global Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
700,000
+31.75%
|
$13,300,000
$19.0 P/Share
|
|
Sep 21
2020
|
Logos Global Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
804,392
+50.0%
|
-
|